Scroll Back to Top
Accessibility
Accessibility
Labcorp branded background. Blue with dots

For Healthcare Providers

Labcorp® Plasma Detect™ 

A whole genome sequencing-based ctDNA test for tumor-informed detection of MRD in patients with stage III colon cancer.

 

Labcorp Plasma Detect is available through our Early Experience Program. 
For more information, please contact your local Labcorp Oncology sales representative or fill out the "Contact Us" form above.

Evaluating disease burden and risk of recurrence in Stage III colon cancer

Unmet clinical need

30% of patients with stage III colon cancer will present with recurrent disease within 5 years after surgery1,2

Current assessment methods, including imaging, clinicopathological evaluations, and blood-based protein biomarkers, serve only as proxies for detecting macrometastatic disease3,4

Molecular residual disease (MRD)5

MRD refers to the subclinical presence of a cancer-associated biomarker indicating a high risk of recurrence, which cannot be detected by standard imaging techniques.

Older gentleman with his grandchild. They are blowing bubbles

What is Labcorp Plasma Detect?*

Labcorp Plasma Detect is a whole genome sequencing (WGS)-based circulating tumor DNA (ctDNA) test that offers tumor-informed molecular residual disease (MRD) detection. This helps oncologists assess the risk of cancer recurrence with high sensitivity. The integrated WGS assay design accelerates time to results, enabling faster treatment decisions.


*The term MRD is often used interchangeably between molecular residual disease and minimal residual disease. Labcorp Plasma Detect detects molecular residual disease, which is defined as the subclinical presence of a cancer-associated biomarker indicating a high risk of recurrence, which cannot be detected by standard imaging techniques. MRD terminology is in accordance with the BLOODPAC Consortium. 
 

 

Tumor-Informed MRD Test
vs. 
Tumor-Naïve MRD Test6

Tumor-informed tests

Tumor-informed tests offer high sensitivity by utilizing tissue from the patient's own tumor. These assays screen for mutations specific to the tumor, providing precise monitoring over time

Tumor-naïve tests

Tumor-naïve tests screen for a broad generic panel of genomic alterations in the blood. These assays provide lower sensitivity but eliminate the need for an initial tumor biopsy

Labcorp Plasma Detect Workflow

On left: Landmark Timepoint Initial ctDNA status at a pre - specified time point: Workflow, Variant detection specific to the patient and MRD detection via ctDNA. Tumor Tissue, Plasma and Buffy Coat, Defines Tumor - informed MRD profile by WGS of: • Tumor DNA | Germline DNA Detect MRD profile by WGS of: • Cell - free DNA. On right: Longitudinal Timepoint Surveillance monitoring: MRD detection via ctDNA, plasma, MRD profile tracking by WGS of: • Cell - free DNA

Labcorp Plasma Detect eliminates the need for custom panel design, resulting in a faster turnaround time for results compared to tumor-informed bespoke* tests that require custom panel design for each patient.

Sample accessioning > Processing & Library Prep > Sequencing > Most tumor informed approaches require bespoke panel creation & Validation > Analysis, Report Generation, and Review

*Bespoke approach refers to custom panel design unique to each patient’s tumor profile

Key benefits of Labcorp Plasma Detect

Icon of a stopwatch

Accelerates time to results

Delivers a 14-day landmark test result and a 7-day longitudinal test result, enabling faster treatment decisions

Icon of a magnifying glass on test tube

Enables recurrence monitoring

Facilitates seamless monitoring through a simple blood draw workflow, offering convenience for both oncologists and patients

Recurrance

Optimizes sensitivity*

Leverages WGS of tumor DNA, White Blood Cells DNA, and cfDNA to detect MRD at low levels with confidence

 

Sensitive

0.005% ctDNA content

Specific

99.4% specificity

 *Sensitivity and specificity data derived from an internal analytical validation study

Integrated WGS assay design provides a high level of sensitivity and specificity while accelerating time to results

Why choose Labcorp Plasma Detect

  • Detects MRD in cfDNA from patients diagnosed with stage III colon cancer

  • Integrated WGS assay design provides a high level of sensitivity and specificity while accelerating time to results

  • Combining Labcorp Plasma Detect with clinicopathological features enhances recurrence risk assessment7

  • Labcorp Plasma Detect demonstrates that ctDNA dynamics is prognostic of recurrence7

 PROVENC3 clinical study7

Labcorp Plasma Detect was the MRD test used in the PROVENC3 study, which was presented at the 2024 AACR Conference. The study’s results underscore the clinical validity of post-surgery ctDNA testing in stage III colon cancer patients.

  • Patients with ctDNA detected post-surgery by Labcorp Plasma Detect are at a higher risk of experiencing a recurrence
  • Combining Labcorp Plasma Detect with clinicopathological features enhances risk assessment 
    • Incorporating post-surgery ctDNA status into clinicopathological risk models significantly enhances the accuracy of predictive models for disease recurrence
    • Low-risk patients who test negative for ctDNA after surgery are at a very low risk of recurrence
       

Labcorp Plasma Detect is available through our Early Experience Program

For more information, please contact your local Labcorp Oncology sales representative.

References

  1. van den Berg, I., Coebergh van den Braak, R.R.J., van Vugt, J.L.A. et al. Actual survival after resection of primary colorectal cancer: results from a prospective multicenter study. World J Surg Onc 19, 96 (2021). https://doi.org/10.1186/s12957-021-02207-4
  2. Siegel RL, Nikita Sandeep Wagle, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. 2023;73(3):233-254. doi:10.3322/caac.21772
  3. Schirripa M, Lenz HJ. Biomarker in colorectal Cancer. Cancer J. 2016;22(3):156–64.
  4. André, T., Boni, C., Mounedji-Boudiaf, L., et al. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. N Engl J Med 2004;350:2343-2351; DOI: 10.1056/NEJMoa032709
  5. Hadd AG, Silvestro A, McKelvey BA, et al. Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium. Clin Transl Sci. 2025 Mar;18(3):e70185. doi: 10.1111/cts.70185. 
  6. Santonja A, Cooper WN, Eldridge MD, et al. Comparison of tumor-informed and tumor-naïve sequencing assays for ctDNA detection in breast cancer. EMBO Mol Med. 2023 Jun 7;15(6):e16505. doi: 10.15252/emmm.202216505
  7. Rubio Alarcón C, Georgiadis A, Franken IA, et al. Clinical validity of post-surgery circulating tumor DNA testing in stage III colon cancer patients treated with adjuvant chemotherapy: The PROVENC3 study. Abstract presented at: AACR Annual Meeting 2024. https://www.abstractsonline.com/pp8/#!/20272/presentation/9742